China Medical Aesthetics Advertising Compliance: The 2026 Guide for International Brands (Advertising Law, Medical Advertising Rules, Xiaohongshu & Douyin)

In mainland China, a medical aesthetics ad must satisfy the Advertising Law, the Medical Advertising Administration Measures, the drug and device ad review rules, the Internet Advertising Measures and SAMR's enforcement guides — and then each platform's own rules. The biggest mistake international brands make is treating a paid influencer post with an "ad" label as compliant. Medical, drug and device ads may not use endorsers at all.

Below: the rule stack, the claims most often imported from home markets, and who is liable. For a phrase-level list, see 10 high-risk claims.

Which rules apply to a medical aesthetics ad in mainland China?

"Medical aesthetics" (医疗美容) is a medical activity in China: Article 2 of the Medical Cosmetology Services Administration Measures (医疗美容服务管理办法) defines it as repairing and reshaping a person's appearance or body using surgery, drugs, medical devices or other invasive or traumatic medical techniques. Advertising it therefore falls under medical advertising rules, not beauty or cosmetics rules.

What does the Advertising Law prohibit in medical aesthetics ads?

Article 16 is the core. Medical, drug and medical device ads may not contain:

1. assertions or guarantees of efficacy or safety;
2. cure rates or effectiveness rates;
3. comparisons with the efficacy and safety of other drugs or devices, or with other medical institutions;
4. recommendations or endorsements by an advertising endorser (广告代言人);
5. other content prohibited by laws and administrative regulations.

Other provisions that matter:

• Article 9, item (3) bans terms such as "national-level" (国家级), "highest-grade" (最高级) and "best" (最佳). SAMR's 2023 Absolute Terms Enforcement Guide allows some context-based leniency, but says absolute terms about efficacy, cure rates or effectiveness in medical, medical aesthetics, drug and device ads are generally not treated as minor violations.
• Article 15 bans advertising for narcotic, psychotropic, toxic-for-medical-use and radioactive drugs entirely, and limits other prescription drugs to medical and pharmaceutical journals designated by the health and drug authorities.
• Article 17 bars any ad other than a medical, drug or device ad from claiming to treat disease or using medical terms. This catches skincare and "beauty salon" copy that borrows clinical language.
• Article 11 requires ad content that involves a licensed matter to match the licence — relevant when a claim goes beyond a product's registered scope.
• Article 46 requires medical, drug and device ads to be reviewed by the competent authority before publication; unreviewed ads may not be published.
• Article 19 bars internet information service providers, among others, from publishing disguised medical, drug or device ads in the form of health or wellness knowledge.

What may a clinic's own advertising contain?

Much less than most marketers expect. Under the Medical Advertising Administration Measures:

• Article 3: a medical institution must obtain a Medical Advertising Review Certificate (医疗广告审查证明) before publishing a medical ad. Article 5: non-medical institutions may not publish medical ads. SAMR's 2025 Work Guide (item 2) restates that only lawfully established medical institutions may publish, or commission others to publish, medical ads.
• Article 6 limits content to eight items: the institution's first name, address, ownership type, institution category, registered clinical departments, number of beds, opening hours and phone number. Items 1–6 must match the institution's practice licence.
• Article 7 bans, among other things, content involving medical techniques, treatment methods, disease names or drugs; guaranteed or implied cures; cure or effectiveness rates; and using patients, health professionals or medical research institutions as testimonials.
• Article 13: the certificate is valid for one year. Article 14: the ad must show the institution's first name and the certificate number.

SAMR's 2021 Medical Aesthetics Advertising Enforcement Guide confirms that medical aesthetics ads are medical ads, and lists enforcement priorities. They include manufacturing "appearance anxiety" (容貌焦虑) by linking poor looks to "incompetence", "laziness" or "poverty", or good looks to "high quality", "diligence" or "success"; advertising drugs or devices not approved or filed with drug regulators; promoting services not approved or filed with health authorities; guaranteeing results or safety; using patients for before/after comparisons; and using endorsers — including so-called "recommendation officers" (推荐官) and "experience officers" (体验官), who it says should be treated as endorsers. The 2025 Work Guide adds that appearance-anxiety content violates Article 9, item (7) (social morality) and is penalised under Article 57.

Why is botulinum toxin a special case?

Since 2008, type A botulinum toxin and its preparations have been managed in China as a toxic drug for medical use (国食药监办〔2008〕405号). NMPA restated in 2025 that this is still the case. That puts it in the first paragraph of Advertising Law Article 15: it may not be advertised at all — not even in professional journals. SAMR Order No. 21 (Article 21) repeats the ban, and Article 6 of the Internet Advertising Measures separately bans prescription drug ads online unless a law or administrative regulation provides otherwise.

Regulators have penalised clinics for promoting toxin treatments by name. In one published case, a WeChat article on delaying wrinkles recommended toxin injections and ended with the clinic's phone number and address; the "education" framing did not help.

Are influencer and KOL posts advertising in China?

Often, yes — and for this category that is where most of the risk sits.

• Labelling: Article 9 of the Internet Advertising Measures requires internet ads to be recognisable as ads. Where goods or services are promoted through knowledge sharing, experience sharing or reviews with a purchase link or other way to buy attached, the publisher must clearly mark it "广告". The same article carves out content that law already prohibits from being advertised — a label does not make banned content lawful.
• Endorsement: a creator who recommends a medical aesthetics product or service in their own name or image is an endorser under Article 2 of the Advertising Law, and Article 16(1)(4) bans endorsers in medical, drug and device ads. Labelling the post "广告" does not fix that.
• Livestreams: Article 35 of the 2026 Live-streaming E-commerce Measures says a person with some influence, other than the seller, recommending goods or services in their own name or image during a livestream generally constitutes commercial advertising, with the corresponding Advertising Law duties.
• Disguised ads: Article 8 of the Internet Advertising Measures bans disguised medical, drug and device ads presented as health knowledge, and says health content may not show the seller's address, contact details or purchase links on the same page or at the same time.

Does passing Xiaohongshu or Douyin review make an ad legal?

No. Platforms verify who is advertising — SAMR's 2025 Work Guide (item 18) requires platform companies to verify in-platform operators offering medical services and self-media producing medical content — and they apply their own content rules, which change often and can be stricter than the law. But platform approval is not the administrative review required by Article 46. Liability under the Advertising Law sits with the advertiser, agency, publisher and endorser regardless of what a moderator approved. Platforms carry their own separate duty: under Article 45, an internet information service provider must stop illegal ads it knows or should know about, and the 2021 Enforcement Guide directs regulators to press platforms to intercept illegal medical aesthetics ads. Check the platform's current rule centre before each campaign rather than relying on last quarter's experience.

What do international brands most often get wrong?

1. Using "FDA-approved" as proof that a product works or is safe. No clause mentions the FDA by name. The risk comes from what the claim does: it implies efficacy or safety (Article 16(1)(1)), and if the product is not registered with NMPA, advertising it is itself an enforcement priority. Safer direction: lead with NMPA registration facts in drug or device ads that carry an approval number. Keep foreign approvals out of consumer copy.

2. Before/after photos and patient stories. In clinic ads they fall under the ban on using patients as testimonials (Measures Article 7, item 6), and the 2021 guide names patient before/after comparisons as an enforcement priority. A patient who appears with a recommendation can also be an endorser. Safer direction: keep case photos in the consultation, with consent, not in ads or seeding posts.

3. Duration and outcome promises ("lasts 18 months", "instant lift"). These are efficacy assertions under Article 16(1)(1). In a device ad they must also stay within the registration certificate and instructions (Order No. 21, Article 6). Safer direction: drop the number from ad copy and explain individual variation in the consultation.

4. Claims outside the NMPA-approved indication. Device ads may not go beyond the registered intended use; drug ads may not go beyond the approved label (Order No. 21, Articles 5–6; Advertising Law Article 11). A filler registered for one indication cannot be advertised for another because it is used that way abroad. Check the registration record before writing copy. See our companion guide on checking NMPA approval for fillers and botulinum toxin.

5. KOL seeding without a medical-ad strategy. A typical home-market brief — creators try the treatment, post their results, tag the brand, add a link and a disclosure — breaks several rules at once: endorser ban, before/after ban, no review certificate or approval number, and possibly an advertiser that is not a medical institution. Safer direction: clinic ads published by the clinic under a review certificate, device or drug ads by the registration holder (or a company it authorises) under an approval number, and genuine education with no contact details, links or brand push.

6. Toxin brand names in consumer content. A case published by Guangzhou's Tianhe District government describes a medical aesthetics hospital penalised under Article 15(1) for an "imported face-slimming" listing on a third-party platform that named a toxin brand. Safer direction: no toxin advertising in any medium, by brand or generic name.

Who is liable when an ad breaks the rules?

• Advertiser (brand or clinic): responsible for the truthfulness of the content (Article 4). For Article 16 violations, Article 58 provides for an order to stop, a fine of 1–3 times the advertising fee (¥100,000–200,000 if the fee cannot be calculated or is clearly too low), rising to 3–5 times (¥200,000–1,000,000) in serious cases, plus possible revocation of the business licence and of the ad approval. The same article covers unreviewed ads (item 14). For banned categories such as toxin ads, Article 57 sets ¥200,000–1,000,000 for the advertiser. False ads under Article 55 start at 3–5 times the fee and can reach 5–10 times (¥1–2 million) for repeat or serious cases.
• Medical institutions can also lose clinical departments or their practice licence for serious violations (Articles 55 and 58, second paragraph).
• Agencies and publishers: must check supporting documents and verify content (Article 34), and are fined if they design, produce, act as agent for or publish an ad they knew or should have known was illegal (Articles 55 and 58, third paragraph).
• Endorsers: confiscation of illegal income plus a fine of 1–2 times that income for endorsing medical, drug or device ads (Article 61).
• Civil liability: for false ads about goods or services affecting consumers' life and health, agencies, publishers and endorsers are jointly liable with the advertiser for consumer harm (Article 56).

What do recent enforcement cases look like?

From official notices:

• Actor as endorser: an actor's "anti-ageing journey" article on a clinic's WeChat account, with a treatment video and before/after images, was found to be endorsement of a medical service under Article 16(1)(4). Shanghai's regulator confiscated ¥54,880 and fined the same amount.
• Toxin "education" article: the clinic case described above was fined ¥20,000 under Article 15(1).
• Livestream "beauty special": an e-commerce partnership promoted picosecond laser, collagen and "face-slimming" injection services in a Weibo livestream, with claims that had not been through ad review; Hangzhou's regulator imposed ¥539,600 in fines and confiscations.

What should you check before publishing?

1. Who is the advertiser — a licensed medical institution, a product registration holder, or neither?
2. Which approval applies — a Medical Advertising Review Certificate, or a drug or device ad approval number? Is it valid, and is the number shown?
3. Does the copy match the approved sample exactly, with no edits, cuts or splicing?
4. Is the product NMPA-registered, and is every claim inside its registered indication or label?
5. Is it, or does it mention, botulinum toxin? If so, do not publish.
6. Any efficacy or safety guarantee, rates, comparisons or absolute terms?
7. Any endorser — influencer, celebrity, patient, doctor, "experience officer"?
8. Any before/after imagery or appearance-anxiety framing?
9. Is "education" content carrying contact details, links or a brand push?
10. Is paid or linked content marked "广告" — and is it allowed to be advertised at all?

Where does Medcxy fit?

Medcxy reviews draft copy sentence by sentence against the rules for mainland China and six other jurisdictions; each flag cites the rule, suggests a rewrite and gives a publish or don't-publish verdict. It also looks up registrations in NMPA, FDA, EUDAMED, PMDA and MFDS records, so claims can be checked against the approved indication. A free tier is available. It supports your review; it does not replace legal advice or the required administrative review.

Related reading

• Medical aesthetics ad compliance: 10 high-risk claims to avoid in 2026
• What is medical aesthetics ad compliance AI? A working definition for 2026
• How to check whether a dermal filler or botulinum toxin is approved by China's NMPA

Sources

• Advertising Law of the PRC (2021 amendment), SAMR
• Medical Advertising Administration Measures, SAMR
• Medical Aesthetics Advertising Enforcement Guide (SAMR Announcement 2021 No. 37)
• Medical Advertising Supervision Work Guide (SAMR, 2025)
• Absolute Terms Enforcement Guide (SAMR Announcement 2023 No. 6)
• Interim Measures for Drug, Device, Health Food and FSMP Ad Review (SAMR Order No. 21), Ministry of Justice
• Internet Advertising Measures (SAMR Order No. 72)
• Live-streaming E-commerce Supervision Measures (SAMR & CAC Order No. 117)
• Medical Cosmetology Services Administration Measures, NHC
• Notice on managing type A botulinum toxin as a toxic drug (2008), NMPA
• NMPA typical cases and consumer notice on botulinum toxin (2025)
• Botulinum toxin advertising case, Tianhe District AMR, Guangzhou (2023)
• Shanghai medical aesthetics typical cases, Shanghai Administration for Market Regulation
• Medical aesthetics typical cases including the Hangzhou livestream case, SAMR (2023)

Compiled from official texts as of October 2026. This is general information, not legal advice; enforcement practice varies by locality, so confirm specific campaigns with counsel and the competent authority.